Overcoming the need for a cold chain with conjugated meningococcal Group C vaccine: A controlled, randomized, double-blind study in toddlers on the safety and immunogenicity of Menjugate®, stored at room temperature for 6 months
- 1 January 2007
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 25 (7), 1175-1182
- https://doi.org/10.1016/j.vaccine.2006.10.022
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Revolutionary vaccine technology breaks the cold chainThe Lancet Infectious Diseases, 2004
- Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysisBMJ, 2003
- Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccineVaccine, 2003
- Can needle-free administration of vaccines become the norm in global immunization?Nature Medicine, 2003
- Impact of meningococcal C conjugate vaccine in the UKJournal of Medical Microbiology, 2002
- Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccinesVaccine, 2002
- Frequency and causes of vaccine wastageVaccine, 2001
- Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000Vaccine, 2001
- Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccinesVaccine, 2000
- A Trial Of A Group A Plus Group C Meningococcal Polysaccharide-ProteinThe Journal of Infectious Diseases, 1995